AZNCF News and Press, AstraZeneca Plc From 08/08/23

2023-08-08 12:46:53 ET Summary China's economic recovery has turned out to be slower than expected, with growth forecasts reduced for 2023. But strong domestic consumption indicates that there are still pockets of recovery. Segments like jewelry, apparel, and medicines are doing w...

2023-08-08 12:10:19 ET AstraZeneca ( OTCPK:AZNCF ) had declared $0.93/share semi-annual dividend. Payable Sept. 11; for shareholders of record Aug. 11; ex-div Aug. 9. See AZNCF Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Astra...

2023-08-07 17:44:22 ET Summary On July 20, Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. However, those results were overshadowed by a federal judge's decision to dismiss a JNJ subsidiary's bankruptcy fili...

2023-07-30 05:55:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund outperformed its benchmark index and the all-cap growt...

2023-07-30 01:20:34 ET Summary AstraZeneca's revenue for the second quarter of 2023 was $11.42 billion, up 5% from the previous quarter and 6% from the second quarter of 2022. At the end of June 2023, AstraZeneca's total debt was about $30.8 billion, down $1.68 billion from the pr...

2023-07-29 10:03:55 ET Summary AstraZeneca's H1 2023 results show robust growth, with revenues ex-COVID-19 medicines increasing by 16% YoY, core EPS by 21%, and gross profit margin of 82%. Oncology and rare disease segments drove growth, with treatments like Tagrisso, Farxiga, and...

2023-07-28 13:34:09 ET AstraZeneca PLC (AZN) Q2 2023 Earnings Conference Call July 28, 2023 06:45 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fredric...

2023-07-28 02:19:52 ET AstraZeneca press release ( NASDAQ: AZN ): Q2 Non-GAAP EPS of $2.15 beats by $1.18 . Revenue of $11.42B (+6.0% Y/Y) beats by $400M . Excluding COVID-19 medicines, Q2 2023 Total Revenue increased by 14% (17% at CER). Core SG&A-to-T...

2023-07-27 09:40:36 ET Summary The news on Starpharma share price is challenging as a significant shareholder exits. The news of commercially interesting developments continues to broaden, meaning that substantial share price upside seems likely. Starpharma has a strong board ...

2023-07-21 11:08:50 ET Summary On July 27, 2023, Bristol-Myers Squibb, one of the leaders in the global cancer and immunology therapeutics market, will release its financial report for the second quarter of 2023. In the first half of 2023, the company delighted investors with nume...